Tradestie Institutional Equity Comparison Engine

OVID vs EVMN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OVID Overall Edge

OVID Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical while EVMN counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, OVID trades at 1.8x Forward P/E with -4693.7% operating margin (-88.3% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, OVID sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner OVID
OVID 1.8x vs EVMN N/M Fwd P/E
Growth & Margin Winner EVMN
Op Margin -4693.7% vs 0.0% ยท YoY -88.3% vs +0.0%
Momentum & Technical Winner OVID
1Y +100.0% vs -61.0% ยท 52W Pos 63% vs 8%
Options & Structure Winner EVMN
CONSOLIDATION (30th %ile IV) vs SURGE (53rd %ile IV)
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.40
-5.51% 1D
Market Cap $479.4M
1M Return +11.63%
1Y Return +100.0%
Forward P/E 1.8x
Unified AI Score
43.5 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 67.0 Mom 50.0
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OVID +100.0% EVMN -61.03% Spread: +161.03 pp (OVID Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OVID Revenue EVMN Revenue OVID Op. Margin EVMN Op. Margin Margin Edge
FY2020 $10M N/A -645.4% N/A OVID
FY2021 $210M N/A 59.6% N/A OVID
FY2022 $0M N/A -3696.4% N/A OVID
FY2023 $0M N/A -15122.7% N/A OVID
FY2024 $0M $10M -10933.7% -1000.2% EVMN
FY2025 $10M $10M -585.2% -623.6% OVID

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OVID (7) vs EVMN (2)
Institutional Metric OVID EVMN Criterion Row Winner
Market Capitalization Scale $479.4M $315.5M Larger Scale OVID
Trailing P/E Ratio Valuation 1.8x N/M Lower Multiple OVID
Forward P/E Ratio Valuation 1.8x N/M Lower Multiple OVID
Revenue Growth (YoY) Growth -88.3% +0.0% Higher Growth EVMN
Operating Margin (TTM) Profitability -4693.7% 0.0% Higher Margin EVMN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -35.4% -69.5% Higher ROE OVID
52-Week Range Position Momentum 63% ($1โ€“$3) 8% ($5โ€“$33) Stronger Trend OVID
Beta / 30D Volatility Risk Regime 0.98ฮฒ ยท 97% Vol 1.05ฮฒ ยท 118% Vol Lower Realized Risk OVID
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite OVID

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OVID vs EVMN Buy Guide
OVID CONSOLIDATION
150d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live OVID Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OVID nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.